24.02.2016 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Outstanding 2015 financial results - 25% dividend increase proposed - Positive Group guidance for 2016 - New stretch targets for 2019


 
Fresenius SE & Co. KGaA / Key word(s): Forecast/Final Results 24.02.2016 07:00 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Group sales increased by 19% (9% in constant currency) to EUR27,626 million (2014: EUR23,231 million). Organic sales growth was 6%. Acquisitions contributed 4% and divestitures reduced sales by 1%. Currency translation had a positive effect of 10%. Group EBIT* increased by 25% (13% in constant currency) to EUR3,958 million (2014: EUR3,158 million). The EBIT margin* increased to 14.3% (2014: 13.6%). Group net income** before special items increased by 31% (21% in constant currency) to EUR1,423 million (2014: EUR1,086 million). Earnings per share** before special items increased by 30% (20% in constant currency) to EUR2.61 (2014: EUR2.01). Group net income** including special items increased by 27% (17% in constant currency) to EUR1,358 million (2014: EUR1,067 million). Earnings per share** including special items increased by 27% (16% in constant currency) to EUR2.50 (2014: EUR 1.97). Based on the strong financial results, the Management Board will propose to the Supervisory Board a dividend increase of 25% to EUR0.55 per share (2014: EUR0.44). For 2016, Fresenius projects sales growth of 6% to 8% in constant currency. Net income*** is expected to grow by 8% to 12% in constant currency. For 2019, Group sales are expected to reach EUR36 billion to EUR40 billion****. Group net income** is expected to increase to EUR2.0 billion to EUR2.25 billion****. * Before special items ** Net income attributable to shareholders of Fresenius SE & Co. KGaA *** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before special items **** At comparable exchange rates; including small and mid-size acquisitions (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., February 24, 2016 End of note 24.02.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 29.083,00 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 39.695,00
EBITDA1,2 5.500,00 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 0,00
EBITDA-Marge3 18,91 18,69 17,04 19,01 19,66 18,27 0,00
EBIT1,4 4.327,00 4.589,00 5.251,00 4.631,00 4.385,00 4.252,00 4.990,00
EBIT-Marge5 14,88 13,69 14,83 12,43 12,09 11,33 12,57
Jahresüberschuss1 2.676,00 1.816,00 1.871,00 1.915,00 2.823,00 1.867,00 2.035,00
Netto-Marge6 9,20 5,42 5,28 5,14 7,78 4,98 5,13
Cashflow1,7 3.574,00 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 5,58
Ergebnis je Aktie8 2,83 3,25 3,37 3,44 3,06 3,26 2,45
Dividende8 0,62 0,75 0,80 0,84 0,88 0,92 0,70
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 27,820 Kaufen 15.669,26
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,65 17,06 0,73 9,52
KBV KCV KUV EV/EBITDA
0,85 3,09 0,42 5,84
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
Hauptversammlung
0,70 0,70 2,52 17.05.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
09.05.2023 02.08.2023 01.11.2022 24.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,31% 5,03% 5,98% -25,48%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE